NextGen Sciences, a leading provider of biomarker discovery, assay development, validation and testing services, and Takeda Pharmaceutical Company (Takeda), have entered into an agreement under which NextGen Sciences will develop validated protein biomarker assays to be used in Takeda’s preclinical and clinical studies to support their drive towards personalised medicine.
The biomarker assays will be designed to target specific protein isoforms found in liver and muscle in multiple species, for use in preclinical studies, and will also be validated for use in clinical studies. NextGen Sciences’ multiple reaction monitoring (MRM) protein assay platform is ideal for studies of this kind, which involve multiple isoforms and multiple species.